Reneo Pharmaceuticals to Participate in SVB Securities Global Biopharma Conference

Rhea-AI Summary

Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM) announced its participation in the upcoming SVB Securities Global Biopharma Conference on February 15, 2023, at 3:40 p.m. EST. This virtual event will showcase Reneo's focus on developing therapies for rare genetic mitochondrial diseases. Their lead product candidate, mavodelpar (REN001), targets mitochondrial dysfunction and aims to enhance ATP production. Webcast links will be available on the company's website.

IRVINE, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced that the company’s management team will participate at the SVB Securities Global Biopharma Conference.

SVB Securities Global Biopharma Conference
Date: Wednesday, Feb. 15, 2023
Location: Virtual
Presentation: 3:40 p.m. EST (webcast)

Links to the presentation will be posted on the Investors section of the Reneo Pharmaceuticals corporate website.

About Reneo Pharmaceuticals

Reneo is a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). Our lead product candidate, mavodelpar (REN001), is a potent and selective agonist of the peroxisome proliferator-activated receptor delta (PPARδ). Mavodelpar has been shown to increase transcription of genes involved in mitochondrial function, increase fatty acid oxidation, and may increase production of new mitochondria. For additional information, please see reneopharma.com.

Contacts:

Joyce Allaire
Managing Director
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com 

David Melamed, Ph.D.
Media Inquiries
Russo Partners, LLC
david.melamed@russopartnersllc.com 

Danielle Spangler
Investor Relations
Reneo Pharmaceuticals, Inc.
dspangler@reneopharma.com 

FAQ

When is Reneo Pharmaceuticals participating in the SVB Securities Global Biopharma Conference?

Reneo Pharmaceuticals will participate in the SVB Securities Global Biopharma Conference on February 15, 2023.

What time will Reneo Pharmaceuticals present at the conference?

Reneo Pharmaceuticals' presentation is scheduled for 3:40 p.m. EST.

Where can I watch Reneo Pharmaceuticals' presentation?

The presentation can be viewed through a webcast, with links posted on Reneo Pharmaceuticals' corporate website.

What is Mavodelpar (REN001) developed by Reneo Pharmaceuticals?

Mavodelpar (REN001) is Reneo Pharmaceuticals' lead product candidate targeting rare genetic mitochondrial diseases.

What is the focus of Reneo Pharmaceuticals?

Reneo Pharmaceuticals focuses on therapies for patients with rare genetic mitochondrial diseases.